Moderna Inc
Stocks making the biggest moves premarket: Hershey, Meta Platforms, Arm Holdings, Shake Shack and more
Check out the companies making headlines in premarket trading. Hershey — Shares were down 7% in the premarket after the chocolate maker posted second-quarter results that missed analyst expectations. The company earned $1.27 per share on revenue of $2.07 billion. Analysts polled by LSEG expected a profit of $1.43 per share on revenue of $2.31 […]
Read More
Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 […]
Read More
S&P 500 futures rise after Meta posts quarterly beat: Live updates
Traders work on the floor of the New York Stock Exchange. NYSE Stock futures rose in overnight trading Wednesday as investors weighed the latest corporate earnings reports, including strong results from Meta Platforms. S&P 500 futures gained 0.4%, while Nasdaq-100 futures jumped 0.7%. Futures tied to the Dow Jones Industrial Average added 30 points, or […]
Read More
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its […]
Read More
Healthy Returns: What we know about the next round of Covid vaccines
New vaccine COMIRNATY® (COVID-19 Vaccine, mRNA) by Pfizer, available at CVS Pharmacy in Eagle Rock, CA. Irfan Khan | Los Angeles Times | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! It’s almost that time of the year again. A new […]
Read More
Moderna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Empty bottles of Moderna’s Covid-19 vaccine. Fred Tanneau | AFP | Getty Images Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release positive phase three data on a […]
Read More
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, […]
Read More
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after spending the last weekend in […]
Read More
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck’s Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. […]
Read More
FDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product
The FDA has approved Moderna’s RSV vaccine for older adults. Courtesy: Moderna The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever product to enter the U.S. market. The decision is a win for Moderna, which desperately needs another revenue source amid […]
Read More